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Abstract
Background: Osteopontin (OPN) is a secreted glyco-
protein that mediates cell–matrix interactions and cel-
lular signaling by binding with integrin (primarily AvB3)
and CD44 receptors. OPN regulates cell adhesion, che-
motaxis, macrophage-directed IL-10 suppression, stress-
dependent angiogenesis, apoptosis prevention, and
anchorage-independent growth of tumor cells. However,
the molecular mechanisms that define the role of OPN
in tumor progression and metastasis are incompletely
understood. Methods: In this study, we use a system of
4T1 and 4T07 murine mammary epithelial tumor cell lines
that are divergent in both metastatic phenotype and OPN
expression. 4T1 expresses OPN and hematogeneously
metastasizes, whereas 4T07 does not express OPN and
is highly tumorigenic but fails to metastasize. Results:
Our results demonstrate that OPN regulates Stat1 pro-
tein degradation through theubiquitin–proteasomepath-
way to alter interferon-;–dependent growth inhibition
and p21 expression. We identify Stat-interacting LIM pro-
tein as the critical Stat ubiquitin E3 ligase in this setting.
Conclusions: OPN regulates Stat1-dependent functions,
such as growth inhibition and p21 expression, in the mu-
rine mammary epithelial cells lines 4T1 and 4T07. This
relationship between OPN and Stat1 in the context of
tumor biology has not been previously examined.
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Introduction
Osteopontin (OPN) is a secreted glycoprotein that is rich in
aspartate and sialic acid residues and contains functional
domains for calcium binding, phosphorylation, glycosyla-
tion, and extracellular matrix adhesion [1]. OPN mediates
cell–matrix interactions and cellular signaling by binding
with integrin (primarily avb3) and CD44 receptors. OPN reg-
ulates cell adhesion, chemotaxis, macrophage-directed IL-
10 suppression, stress-dependent angiogenesis, apoptosis
prevention, and anchorage-independent growth of tumor
cells [1–4]. Recently, a substantial body of data has linked
OPN with the regulation of tumor growth and metastatic
spread [5]. However, the molecular mechanisms that de-
fine the role of OPN in tumor progression and metasta-
sis are incompletely understood. In a previous study using
endotoxin-stimulated murine macrophages, we demonstrated
that OPN increases Stat1 ubiquitination and subsequent 26S
proteasome–mediated degradation to inhibit Stat1-dependent
cellular functions [6]. Stat-interacting LIM (SLIM) protein is
the Stat ubiquitin (Ub) E3 ligase critical for Stat1 degradation.
OPN had not been previously linked to Stat1 degradation, and
our results suggest OPN to be a unique and as yet poorly
characterized transactivator of Stat1 degradation by the Ub–
proteasome system.
In a similar fashion, the potential relationship between OPN
and Stat1 has not been previously studied in tumor biology.
Stat1 is thought to possess tumor-suppressor functions. In the
present study, we examine OPN-dependent Stat1 expression
in the murine mammary epithelial tumor cell lines 4T1 and
4T07. Our results indicate that OPN regulates Stat1-dependent




N-Carbobenzoxyl-L-leucinyl-L-norleucinal (MG132) and M2
anti-FLAG (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) agarose were
purchased from Sigma-Aldrich (St. Louis, MO). Recombinant
mouse interferon g (IFN-g) and anti–mouse OPN antibody
were purchased from R&D Systems (Minneapolis, MN). Anti-
bodies against Stat1 p84/p91, actin, p21, and Ub were
obtained from Santa Cruz Biotechnologies (Santa Cruz, CA).
Hemagglutinin (HA) monoclonal antibody (3F10) was obtained
from Roche Applied Science (Indianapolis, IN). Rabbit anti–
mouse SLIM serum has been previously described [7].
Cell Lines
Mouse mammary tumor cell lines 4T1 and 4T07 were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum, penicillin (100 U/ml), and
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streptomycin (100 mg/ml), and maintained at 37jC in a hu-
midified atmosphere of 5% CO2. These cells are thioguanine-
resistant sublines derived from the parental population of
410.4 cells from Balb/cfC3H mice [8]. They are heteroge-
neous in their metastatic behavior and expression of OPN.
4T1 expresses OPN and hematogeneously metastasizes to
the lung, liver, bone, and brain, whereas 4T07 does not ex-
press OPN and is highly tumorigenic but fails to metastasize.
Plasmid Constructs
Full-length Stat1 cDNA (U06924) was obtained by re-
verse transcription–polymerase chain reaction (RT-PCR)
with primers Stat1-F 5V-ACGAAGCTTATGTCACAGTGG-
TTCGAGCTTCAG-3V and Stat1-R 5V-ACGAAGCTTTTA-
CACTTCAGACACAGAAATCAAC-3V; the 2250-bp fragment
was inserted into the pCMV-FLAG2 vector (Sigma-Aldrich).
OPN cDNA (J04806) was amplified by RT-PCR with primers
OPN-F 5V-CGCGAATTCCATGAGATTGGCAGTGATTTG-3V
and OPN-R 5 V-CGCGGATCCTTAGTTGACCTCAG-
AAGATG-3V; the 885-bp fragment was inserted into the
mammalian expression vector pcDNA3.1/HisB (Invitrogen,
Carlsbad, CA). HA/Ub plasmid was kindly provided by
Dr. Bohmann (University of Rochester, Rochester, NY).
PathDetect GAS cis-reporting vector was purchased from
Stratagene (La Jolla, CA).
RNAi for OPN and SLIM
Using GenBank sequence NM_009263 for murine OPN
cDNA and computer analysis software (Ambion, Austin, TX),
we selected a candidate sequence in the OPN cDNA se-
quence for RNAi, 5V-AAGTCAGCTGGATGAACCAAG-3V.
This 21-nt sequence exhibits no homology with other known
mouse genes. Synthetic annealed siRNA oligonucleotides
were synthesized chemically, gel electrophoresis–purified,
and used during transient transfection experiments. In a sim-
ilar fashion, siRNA was selected for SLIM (NM_145978): 5V-
AAGAUCCGACAGAGCGCCUCA-3V. A mismatch (MM)
hairpin siRNA with limited homology to mouse genes served
as the siRNA negative control.
Transient Transfection and Luciferase Assay
DNA transfections were carried out in 12-well plates using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Briefly, 1 
106 4T1 and 4T07 cells were plated on a 12-well plate and
allowed to grow for 24 hours before transfection. Two micro-
grams of PathDetect GAS cis-reporting plasmid diluted in
OPTI-DMEM and 3 ml of Lipofectamine 2000 diluted in OPTI-
DMEM were combined and incubated at room temperature
for 20 minutes. Cells with transfection reagents were incu-
bated for 4 hours at 37jC in a CO2 incubator. Transfection
medium was then replaced with DMEM containing 10% fetal
bovine serum. At least 24 hours later, the medium was
changed, and cells were stimulated with 500 U/ml IFN-g for
12 hours. To control transfection efficiency between groups,
0.1 mg of pRL-TK was added to each well. Cells were har-
vested in 0.4 ml of reporter lysis buffer (Promega, Madison,
WI), and dual-luciferase reporter assays were performed by
following the protocol provided by the manufacturer.
Immunoblot Analysis
4T1 and 4T07 cells were lysed in buffer [0.8% NaCl,
0.02 KCl, 1% sodium dodecyl sulfate (SDS), 10% Triton
X-100, 0.5% sodium deoxycholic acid, 0.144% Na2HPO4,
and 0.024% KH2PO4, pH 7.4] and centrifuged at 12,000g for
10 minutes at 4jC. Protein concentration was determined by
absorbance at 650 nm using a protein assay reagent. Cell
lysates (50 mg/lane) were separated by SDS–12% polyacryl-
amide gel electrophoresis, and products were electrotrans-
ferred to polyvinylidene difluoride membrane (Amersham
Pharmacia, Piscataway, NJ). The membrane was blocked
with 5% skim milk PBS–0.05% Tween for 1 hour at room
temperature. After being washed thrice, blocked membranes
were incubated with primary antibody for 1 hour at room
temperature, washed thrice in PBS–0.05% Tween, and incu-
bated with horseradish peroxidase–conjugated secondary
antibody for 1 hour at room temperature. After three additional
washings, bound peroxidase activity was detected by the
ECL detection system (Amersham Pharmacia).
Coimmunoprecipitation (co-IP)
4T1 and 4T07 cells were transfected with FLAG/Stat1 ex-
pression plasmid and/or HA/Ub expression plasmid; in some
cases, OPN and SLIM siRNAwere transfected. After 36 hours
of transfection, cells were stimulated with 10 mM MG132 or
DMSO control for 2 hours, washed with cold phosphate-
buffered saline, and lysed for 15 minutes on ice in RIPA lysis
buffer (1 PBS, 1% Nonidet P-40, 0.5% sodium deoxycho
late, and 0.1% SDS) containing protease inhibitors. Cell lysates
were cleared by centrifugation (4jC, 20 minutes, 13,000 rpm).
Immunoprecipitation was performed with 1000 mg of cell lysate
and 40 ml of M2 anti-FLAG agarose, according the method
provided by the manufacturer (Sigma-Aldrich). After five wash-
ings with lysis buffer, immunoblotting was performed with HA
monoclonal antibody or Ub antibody, as described.
Proliferation Assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay was performed using the CellTiter 96
AQueous One Solution Cell Proliferation Assay kit (Promega)
according to the manufacturer’s instructions. Briefly, 4T1 and
4T07 cells transfected with various plasmids or siRNA were
plated in a 96-well plate at 2  103 cells/well. The cells were
treated with 1000 U/ml IFN-g. Three days after treatment, an
MTT assay was performed.
Statistical Analysis
Data are expressed as mean ± SEM. Analysis was per-
formed using two-tailed Student’s t test. P < .05 was consid-
ered significant.
Results
Differential Expression of OPN, Ub-Stat1, and Total Stat1
Protein between 4T1 and 4T07 Cells
Stat1 protein expression in 4T1 and 4T07 cells was
determined (Figure 1A). In 4T1 cells, Stat1 protein was not
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detected in either cell lysate or nuclear fraction. In contrast,
Stat1 protein was found in 4T07 nuclear and cell lysate frac-
tions. When samples were then probed for OPN protein, 4T1
cells expressed a large amount of OPN in both cell lysate
and culture medium. In 4T07, OPN protein was > 10-fold less
than that seen in 4T1 cells. Stat1 steady-state mRNA ex-
pressionwas equivalent between the two cell types (Figure 1B).
As the Ub–proteasome system is one pathway by which Stat1
protein is degraded, co-IP studies were performed to assess
the extent of Ub-associated Stat1 (Figure 1C). Cells were tran-
siently transfected with FLAG/Stat1 and HA/Ub; MG132, a 26S
proteasome inhibitor, was also added. In control 4T1 cells, trace
amounts of Ub-Stat1 are found; in the presence of MG132,
there is a 25-fold increase in Ub-Stat1. In contrast, Ub-Stat1 is
not found in 4T07 cells in the absence or in the presence of
MG132. Inhibitors of calpains (calpastatin, 5 mM) and lyso-
somal enzymes (leupeptin, 50 mM) had no effect on Ub-Stat1 in
4T1 and 4T07 cells (data not shown). These results indicate
that 4T1 expresses more OPN, more Ub-Stat1, and less total
Stat1 in comparison to 4T07. The differences between 4T1 and
4T07 Stat1 expression may result from differences in Ub–
proteasome–mediated Stat1 degradation.
OPN Regulates Ub-Dependent Stat1 Degradation
through CD44
We then proceeded to examine the potential relationship
between OPN and Stat1 expression. 4T1 cells were treated
with siRNA to OPN or MM siRNA control, and co-IP assay
was performed (Figure 2A). When compared to MM-treated
cells, inhibition of OPN expression significantly decreased
the levels of Ub-Stat1 in both the presence and the absence
of MG132. Western blot analysis of 4T1 cell lysates confirms
the efficacy of OPN siRNA in the ablation of OPN expression
(Figure 2B). A converse experiment was performed in 4T07
cells, which do not typically express OPN. 4T07 cells were
transiently transfected with an OPN expression vector or an
empty vector (Figure 2C). In 4T07 cells, the presence of OPN
increased Ub-Stat1 by > 10-fold in the presence of MG132.
These data indicate an essential role for OPN in the forma-
tion of Ub-Stat1. To delineate the cell surface receptor that
mediates this effect, co-IP studies were performed in 4T1
cells in the presence of a blocking antibody to CD44 or a
competitive inhibitor aVb3 integrin receptor binding, RGD
(Figure 2D). Blockade of CD44 binding restored the Ub-
Stat1 profile to that seen with untreated control 4T1 cells,
suggesting that extracellular OPN mediates Stat1 ubiquiti-
nation through the CD44 cell surface receptor.
Functional Correlation of OPN with Stat1-Dependent
Promoter Activity, p21 Expression, and Cell Proliferation
Using IFN-g treatment, functional correlative studies
examined the effect of this OPN–Stat1 pathway on IFN-
regulated Stat1 (GAS)–dependent luciferase activity, p21 pro-
tein expression, and cell proliferation, as measured by MTT
activity, in 4T1 and 4T07 cells (Figure 3). In 4T1 cells trans-
fected with MM siRNA and a consensus GAS-luciferase
reporter plasmid, exposure to IFN (1000 U/ml  12 hours) in-
creased luciferase activity by 10-fold (Figure 3A). When OPN
Figure 1. (A) OPN and Stat1 protein expression in 4T1 and 4T07 cell lysates
and culture media. The mouse mammary tumor cell lines 4T1 and 4T07 were
cultured. Cells were lysed and centrifuged. For media analysis, serum-free
DMEM was centrifuged to remove cellular materials and was concentrated
100-fold. Cell lysates (50 g/lane) were separated by SDS–12% poly-
acrylamide gel electrophoresis, and products were electrotransferred to
polyvinylidene difluoride membrane. After blocking and washing, membranes
were incubated with primary antibody, washed, and incubated with horse-
radish peroxidase–conjugated secondary antibody. Bound peroxidase
activity was detected. The blot is representative of three experiments. (B)
Steady-state Stat1 mRNA expression in 4T1 and 4T07 cells. Total RNA was
isolated and reverse-transcribed into cDNA. cDNA were used in subsequent
PCRs; the primers for Stat1 were 5 V-CTTATTCCATGGACAAGGTTTTG-3 V
(forward) and 5 V-GGTGCTTCTTAATGAGCTCTAGG-3 V (reverse). The gel
is representative of three experiments. (C) co-IP of Ub-Stat1 in 4T1 and
4T07 cells. 4T1 and 4T07 cells were transfected with FLAG/Stat1 expres-
sion plasmid, HA/Ub expression plasmid, and/or empty expression plas-
mids. Full-length Stat1 cDNA (U06924) was obtained by RT-PCR with the
following primers: Stat1-F 5 V-ACGAAGCTTATGTCACAGTGGTTCGAGCT-
TCAG-3 V and Stat1-R 5 V-ACGAAGCTTTTACACTTCAGACACAGAAATCA-
AC-3 V; the 2250-bp fragment was inserted into the pCMV-FLAG2 vector
(Sigma-Aldrich). HA/Ub plasmid was kindly provided by Dr. Bohmann (Uni-
versity of Rochester). After 36 hours of transfection, cells were stimulated
with 10 M MG132, an inhibitor of 26S proteasome function, or DMSO con-
trol for 2 hours; washed; and lysed for 15 minutes on ice in RIPA lysis
buffer. Immunoprecipitation were performed with 1000 g of cell lysate and
40 l of M2 anti-FLAG agarose (Sigma-Aldrich). Immunoblotting was per-
formed with HA or Ub antibody, as described. Blots are representative of
three experiments.
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siRNA was substituted for MM siRNA, IFN increased lucif-
erase activity by 40-fold in comparison (P < .01, 4T1 + IFN vs
4T1). In addition, luciferase activity in 4T1 + IFN with OPN
siRNA was also four-fold greater than that seen in 4T1 + IFN
with MM siRNA (P < .01). Converse experiments were then
performed, in which 4T07 cells were transfected with an OPN
expression vector. In this instance, IFN treatment increased
GAS-luciferase activity by 10-fold in 4T07 cells transfected
with control (empty) expression vector (P < .01). When trans-
fected with an OPN expression vector, IFN-treated 4T07
cells exhibited a five-fold increase in GAS-luciferase activity
(P < .01, 4T07 + IFN + OPN vector vs 4T07 + OPN vector).
However, this level of luciferase activity was two-fold less
than that seen with 4T07 + IFN + control vector (P < .01). In
these gain-of-function and loss-of-function experiments, our
results indicate that OPN expression is associated with
decreased GAS promoter activation. We then proceeded
with a Western blot analysis of p21 and Stat1 protein ex-
pression; p21-mediated growth inhibition is induced by acti-
vated Stat1 in response to IFN stimulation [9] (Figure 3B). In
4T1 cells, minimal p21 and Stat1 were seen in untreated
cells; siRNA ablation of OPN expression was associated with
increased p21 and Stat1 protein expressions in both the ab-
sence and the presence of IFN stimulation. In 4T07 cells,
Stat1 and p21 were readily detected in the unstimulated
state. Transfection of an OPN expression vector was asso-
ciated with decreased Stat1 and p21 proteins in the absence
and in the presence of IFN simulation. These data suggest
that OPN regulates Stat1 and p21 expression. Finally, cell
proliferation in 4T1 and 4T07 cells was measured by MTT
activity (Figure 3C). In 4T1 cells, siRNA ablation of OPN ex-
pression did not alter the extent of 4T1 proliferation; how-
ever, in the setting of IFN stimulation, ablation of OPN in
4T1 cells is associated with a 40% decrease in prolifera-
tion (P < .01, 4T1 + IFN + OPN siRNA vs 4T1 + IFN + MM
siRNA and 4T1 + OPN siRNA). In wild-type and control
vector–transfected 4T07 cells, IFN treatment was associ-
ated with a 42% decrease in proliferation (P < .01, 4T07 +
IFN vs 4T07). When transfected with an OPN expression
vector, 4T07 proliferation was not altered when compared
to 4T07 + control vector. However, in the presence of IFN,
the proliferation of 4T07 + OPN vector cells was restored
Figure 2. (A) Co-IP of Ub-Stat1 in 4T1 cells. Co-IP was performed as previously described for Figure 1C. Cells were also transiently transfected with OPN siRNA.
Using GenBank sequence NM_009263 for murine OPN cDNA, we selected a candidate sequence in the OPN cDNA sequence for RNAi, 5 V-
AAGTCAGCTGGATGAACCAAG-3 V. This 21-nt sequence exhibits no homology with other known mouse genes. Synthetic annealed siRNA oligonucleotides
were synthesized. MM hairpin (MM siRNA) with limited homology to mouse genes served as the siRNA negative control. Blots are representative of three
experiments. (B) OPN and Stat1 protein expression in 4T1 cell lysate. Cells were transfected with OPN siRNA or MM siRNA, as described above. The blot is
representative of three experiments. (C) Co-IP of Ub-Stat1 in 4T07 cells. Co-IP was performed as previously described for Figure 1C. Cells were also transiently
transfected with an OPN expression vector. OPN cDNA was amplified by RT-PCR with primers OPN-F 5 V-CGCGAATTCCATGAGATTGGCAGTGATTTG-3 V and
OPN-R 5 V-CGCGGATCCTTAGTTGACCTCAGAAGATG-3 V; the 885-bp fragment was inserted into the mammalian expression vector pcDNA3.1/HisB (Invitrogen).
Empty expression vector (Vector) was used as negative control. The blot is representative of three experiments. (D) Co-IP of Ub-Stat1 in 4T1 cells with blockade of
CD44 or integrin receptors. Co-IP was performed as previously described for Figure 1C. 4T1 cells were treated with blocking antibody to CD44 or RGD, a
competitive ligand inhibitor of integrin binding. The blot is representative of three experiments.
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to a level equivalent to that noted in the absence of IFN.
These results indicate that IFN-mediated inhibition of cell
proliferation is downregulated by OPN expression in 4T1
and 4T07 cells. In total, these experiments indicate that
OPN-regulated Stat1 protein expression carries functional
implications for cellular proliferation, p21 expression, and
Stat1-dependent promoter activation.
SLIM Regulates Ub-Dependent Stat1 Degradation
SLIM protein is a critical Ub E3 ligase for Stat1 degrada-
tion [7]. To determine the potential relationship between
SLIM and OPN expression in our 4T1/4T07 model, Western
blot analysis initially demonstrated that SLIM expression was
equivalent in 4T1 vs 4T07 cells (data not shown). When
siRNA was used to ablate SLIM in 4T1 cells, IFN-stimulated
Figure 3. (A) IFN-mediated Stat1 binding to GAS consensus-binding element in 4T1 and 4T07 cells. About 1  106 cells were plated on a 12-well plate and allowed
to grow for 24 hours before transfection. In selected instances, cells were treated with IFN-c (1000 U/ml) for 12 hours. Cells with transfection reagents were
incubated for 4 hours. To control transfection efficiency between groups, 0.1 g of pRL-TK was added to each well. Cells were harvested, and dual-luciferase
reporter assays were performed. The PathDetect GAS cis-reporting vector was purchased from Stratagene. 4T1 cells were examined in the presence of OPN
siRNA or MM siRNA; 4T07 cells were examined in the presence of an OPN expression vector or an empty control expression vector. Data are presented as the
mean ± SEM of three separate experiments (*P < .01, 4T1 + IFN vs 4T1 and 4T07 + IFN vs 4T07; **P < .01, 4T1 + IFN + MM siRNA vs 4T1 + IFN + OPN siRNA
and 4T07 + IFN + MM siRNA vs 4T07 + IFN + OPN siRNA). (B) IFN-mediated Stat1 and p21 protein expression in 4T1 and 4T07 cells. Stat1 and p21 protein
expression was determined by Western blot analysis. Antibodies to Stat1 p84/p91, actin, and p21 were obtained from Santa Cruz Biotechnologies. 4T1 cells were
examined in the presence of OPN siRNA or MM siRNA; 4T07 cells were examined in the presence of an OPN expression vector or an empty control expression
vector. The blot is representative of three experiments. (C) IFN-mediated inhibition of cell proliferation in 4T1 and 4T07 cells. MTT assay was performed using the
CellTiter One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer’s instructions. Briefly, 4T1 and 4T07 cells and cells transfected with
various plasmids or siRNA were plated on a 96-well plate at 2  103 cells/well. The cells were left untreated or were treated with 1000 U/ml IFN-c. Three days after
treatment, MTT assay was performed. Data are presented as the mean ± SEM of three separate experiments. (**P < .01, 4T1 + IFN + MM siRNA vs 4T1 + IFN +
OPN siRNA and 4T1 + OPN siRNA, 4T07 + IFN + MM siRNA vs 4T07 + IFN + OPN siRNA; *P < .01, WT 4T07 + IFN vs WT 4T07).
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Stat1 and p21 protein expression was significantly increased
by more than 5-fold and 10-fold, respectively (P < .01, con-
trol versus IFN; Figure 4A). Co-IP studies were then per-
formed in SLIM siRNA– treated 4T1 cells transiently
transfected with FLAG/Stat1 and HA/Ub (Figure 4B). With
increasing SLIM siRNA concentrations, the levels of Ub-
Stat1 progressively decreased until none was noted in the
presence of 100 nM SLIM siRNA. To assess the interplay
between OPN and SLIM, co-IP studies were repeated in
4T07 cells that were transiently transfected with an OPN
expression vector (Figure 4C). OPN expression was asso-
ciated with increased Ub-Stat1, as expected. However, Ub-
Stat1 signal is ablated in the presence of 100 nM SLIM
siRNA. These data indicate that OPN-dependent SLIM
activity regulates Ub-associated Stat1 degradation.
Discussion
OPN is a secreted glycoprotein that is rich in aspartate and
sialic acid residues and contains functional domains for
calcium binding, phosphorylation, glycosylation, and extra-
cellular matrix adhesion [1]. OPN appears to mediate cell–
matrix interactions and cellular signaling by binding with
integrin (primarily avb3) and CD44 receptors. OPN is ex-
pressed in multiple species, including humans and rodents
[10]. Cells that express OPN include osteoclasts; osteo-
Figure 4. (A) Effect of SLIM on Stat1 and p21 protein expression in IFN-treated 4T1 cells. Stat1 and p21 protein expression was determined by Western blot
analysis. An siRNA was selected for SLIM (NM_145978): 5 V-AAGAUCCGACAGAGCGCCUCA-3 V. MM hairpin siRNA with limited homology to mouse genes
served as the siRNA negative control. The blot is representative of three experiments. (B) The effect of SLIM on Ub-Stat1 in 4T1 cells. Co-IP was performed as
previously described. Increasing concentrations of SLIM siRNA (25, 50, and 100 nM) were transfected. The blot is representative of three experiments. (C) The
effect of SLIM and OPN in 4T07 cells. Co-IP was performed as previously described. 4T07 cells were transiently transfected with an OPN expression vector, and
Ub-Stat1 was measured in the presence or in the absence of MG132. In selected instances, SLIM siRNA (100 nM) was added. The blot is representative of three
experiments.
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blasts; kidney, breast, and skin epithelial cells; nerve cells;
vascular smooth muscle cells; and endothelial cells [1,3,4,
11,12]. Activated immune cells such as T cells, NK cells,
macrophages, and Kupffer cells also express OPN. The
secreted OPN protein is widely distributed in plasma, urine,
milk, and bile [13–15]. Constitutive expression of OPN exists
in several cell types, but induced expression is detected in
T lymphocytes, epidermal cells, bone cells, macrophages,
and tumor cells in remodeling processes such as inflam-
mation, ischemia–reperfusion, bone resorption, and tumor
progression [1,3,4]. A variety of stimuli, including phorbol
12-myristate 13-acetate, 1,25-dihydroxyvitamin D, basic fi-
broblast growth factor, tumor necrosis factor-a, IL-1, IFN-g,
and lipopolysaccharide, appears to upregulate OPN ex-
pression [1–4]. OPN has multiple molecular functions that
mediate cell adhesion, chemotaxis, macrophage-directed
IL-10 suppression, stress-dependent angiogenesis, apop-
tosis prevention, and anchorage-independent growth of tu-
mor cells [1–4]. With regard to our findings, we define OPN
to be a unique and as yet poorly characterized transacti-
vator of Stat1 degradation by the Ub–proteasome system.
A relationship between OPN and Stat1 has not been previ-
ously identified.
Stat1 is required for signaling by IFNs, which serve as
potent inhibitors of growth and promoters of apoptosis.
Although Stat1-deficient mice develop no spontaneous tu-
mors, they are highly susceptible to chemical carcinogen–
induced tumorigenesis. Crossing Stat1 mutation into a
p53-deficient background yields animals that develop tu-
mors more rapidly and possess a broader spectrum of tumor
types than is seen with p53 single mutants. Because tumors
from carcinogen-treated wild-type animals also grow far
more rapidly when transplanted into Stat1-deficient ani-
mals than they do in a wild-type host, it appears that Stat1
is needed for the host’s tumor-surveillance capabilities. The
requirement of Stat1 for apoptosis and growth arrest in some
cell types may be explained by its ability to upregulate
caspases and the cdk inhibitor p21 [16,17]. It is well known
that cells deficient in Stat1 are unable to induce growth ar-
rest in response to IFN and that Stat1 activates the tran-
scription of the cyclin D kinase inhibitor p21 [9,17–19]. As a
result, Stat1 is considered to be a tumor suppressor. In the
present study, our observation that OPN, a tumor progres-
sion and metastasis protein, accelerates Stat1 degradation
is consistent with its growth-enhancing effects as an inhib-
itor of apoptosis.
Stat signaling is tightly regulated, and several mecha-
nisms have been proposed to account for this control [20].
The suppressor of cytokine signaling (SOCS) and protein
inhibitor of Stat (PIAS) families of proteins have been shown
to bind to and inhibit either the cytokine receptor–associated
Janus kinase (JAK) or activated Stat molecule, respectively.
SOCS proteins are induced following cytokine stimulation,
bind to JAK kinases, and inhibit activated JAK kinases from
further phosphorylating Stat proteins [21,22]. As a result of
inhibition by SOCS proteins, Stat signaling becomes a
transient response, and levels of phosphorylated Stat pro-
teins decrease within hours of activation. However, the
SOCS feedback mechanism does not result in reduced
levels of Stat proteins. Each member of the PIAS family
has been shown to inhibit Stat-mediated gene activation.
Another mechanism that is known to downregulate Stat
signaling involves tyrosine phosphatases, such as SHP-1
and SHP-2. These tyrosine phosphatases have been shown
to downregulate the activity of Stat1, Stat3, or Stat5 following
activation by IFN-g, leukemia-inhibitory factor, or IL-2 either
by dephosphorylating Stat proteins directly or by dephos-
phorylating JAK kinases [23–25]. Like the SOCS feedback
and PIAS mechanisms, downregulation through tyrosine
phosphatases also does not lead to reduced levels of Stat
proteins. Other posttranslational modifications of Stat pro-
teins, such as arginine methylation, acetylation, and ubiquiti-
nation, have been suggested as important means to regulate
Stat signaling. Polyubiquitination of substrates targets them
for degradation by the 26S proteasome. E3 Ub ligases confer
specificity to ubiquitination reaction. E3 ligase transfers Ub
from the E2 enzyme to a lysine residue on a substrate
protein, resulting in an isopeptide bond between the sub-
strate lysine and the C-terminus of Ub. Ub ligation provides
the key step of substrate selection and Ub transfer to the
protein target. There are at least four classes of E3 ligases:
HECT-type, RING-type, PHD-type, and U-box–containing.
For a specific substrate, E3 ligase is the only member of
the E1, E2, and E3 sequence that undergoes regulation
[26,27]. SLIM contains a PDZ domain and a LIM domain,
and interacts in the nucleus with tyrosine-phosphorylated
Stat molecules [28]. The LIM domain forms a zinc-finger
structure related to the RING finger and PHD structures;
similar proteins have been shown to possess E3 ligase
activity [28]. SLIM inhibits gene expression mediated by
Stat4 or Stat1 by promoting ubiquitination and degradation
of Stat4 and Stat1. The cDNA-encoding mouse SLIM is
1509 bp (GenBank BC024556) for mice, with an open
reading frame of 349 amino acids [7,28]. It is expressed as
a 38-kDa nuclear protein. The human transcript (GenBank
NM_021630) is homologous to the mouse transcript, with
77% identity at the amino acid level and 79% identity at
the cDNA level. It is highly expressed in lung, spleen, thy-
mocyte, and primary hematopoietic cells, including macro-
phages. SLIM is the first identified Ub ligase with specificity
for Stat proteins.
Using a system of lipopolysaccharide-treated RAW264.7
macrophages, we have previously demonstrated that OPN
regulates the Ub-dependent degradation of Stat1 through
the activity of SLIM as Ub E3 ligase [6]. This regulation of
Stat1 degradation underlies OPN’s effect as an inhibitor of
inducible nitric oxide synthase gene transcription. These
were novel findings that defined OPN as a unique and as
yet poorly characterized transactivator of Stat1 degradation
by the Ub–proteasome system. Initially characterized by
Tanaka et al. [7], SLIM inhibits the gene expression mediated
by Stat4 or Stat1 by promoting ubiquitination and degrada-
tion of Stat4 and Stat1. The cDNA-encoding mouse SLIM is
1509 bp (GenBank BC024556) for mice, with an open
reading frame of 349 amino acids [7,28]. It is expressed as
a 38-kDa nuclear protein. The human transcript (GenBank
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NM_021630) is homologous to the mouse transcript, with
77% identity at the amino acid level and 79% identity at the
cDNA level. It is highly expressed in lung, spleen, thymocyte,
and primary hematopoietic cells, including macrophages.
SLIM is the first identified Ub E3 ligase with specificity for
Stat proteins. SLIM has not been previously examined in the
context of OPN-regulated cancer biology.
The signal transduction pathway that links OPN and SLIM
is unknown. There are two possibilities. In the first possibility,
OPN may induce the expression of SLIM, which is constitu-
tively active. A second and more likely possibility is that OPN
may simply activate constitutively expressed SLIM by a post-
translational mechanism. Given our results indicating equiv-
alent SLIM protein expression between 4T1 and 4T07, it
appears that SLIM is indeed constitutively expressed and
that OPN may therefore activate SLIM by posttranslational
modification. As OPN is a secreted protein that binds to
CD44 to ubiquitinate Stat1 in this system, future studies
delineating OPN–SLIM relationships must begin at the level
of OPN’s interaction with CD44 at the cell surface.
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